Enzymes Market Report 2026

The enzymes market size has grown rapidly in recent years. It will grow from $15.2 billion in 2025 to $17.29 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to rising demand for therapeutic enzymes, development of microbial fermentation technology, increasing research in biotechnology, adoption of enzyme-based diagnostics, expansion of pharmaceutical manufacturing,.

The enzymes market size is expected to see rapid growth in the next few years. It will grow to $28.7 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growth in personalized medicine, advances in protein engineering, rising demand for industrial enzymes in food and beverage, increasing focus on sustainable enzyme production, expansion of emerging markets in asia-pacific. Major trends in the forecast period include enzyme engineering and protein design, industrial enzyme applications expansion, personalized enzyme therapy, microbial enzyme innovation, green and sustainable enzyme production.

The growing prevalence of cancer requiring drug-metabolizing enzymes (DMEs) for chemotherapy is expected to drive growth in the enzyme market in the coming years. Enzymes play a key role in destroying cancer cells and breaking down tumors. The expression and function of DMEs in tumor tissues and metabolic organs of cancer patients are crucial, particularly for those with limited response to anticancer drugs and chemotherapy. For example, in September 2025, the American Cancer Society, a US-based professional organization, estimated that 313,780 new cases of prostate cancer will occur in the United States in 2025. The risk of developing prostate cancer rises sharply with age, from 0.2% in men under 50 to 6.5% in men aged 70-79. Therefore, the increasing prevalence of cancers treatable with therapeutic enzymes is expected to fuel growth in the enzyme market.

Leading companies in the enzyme market are developing innovative therapies, such as Lamzede, to better serve patients. Lamzede (velmanase alfa) is used to treat alpha-mannosidosis, a rare genetic disorder caused by deficient lysosomal alpha-galactosidase-A enzyme activity. In May 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical company, received FDA approval for Lamzede to treat non-neurological symptoms in patients with mild-to-moderate alpha-mannosidosis. Lamzede is a recombinant human alpha-mannosidase produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology and represents the first enzyme replacement therapy approved in the U.S. for non-central nervous system manifestations of the disorder.

In February 2023, AstraZeneca, a US-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.3 billion. The acquisition strengthens AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor for lowering blood pressure in treatment-resistant hypertension. CinCor Pharma Inc. is a US-based biotechnology company developing enzyme-based therapeutics.

Major companies operating in the enzymes market are Novozymes A/S, DuPont Industrial Biosciences, BASF SE, Koninklijke DSM N.V., Chr. Hansen Holding A/S, Roche Holding AG, Advanced Enzyme Technologies Ltd., AB Enzymes GmbH, Codexis Inc., Dyadic International Inc., Amano Enzyme Inc., Adisseo France SAS, Biocatalysts Ltd., Amano Enzyme Inc., Enzyme Development Corporation, Creative Enzymes, Hayashibara Co. Ltd., Thermo Fisher Scientific Inc., Associated British Foods Plc, Lonza Group AG, Novus International Inc., Epygen Biotech, DSM Nutritional Products AG, Soufflet Biotechnologies SAS, Beijing Leili Marine Bioindustry Inc., Jiangsu Boli Bioproducts Co. Ltd.

North America was the largest region in the enzymes market in 2025. The regions covered in the enzymes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the enzymes market by increasing the cost of imported raw materials, laboratory equipment, and specialized production machinery. This has slowed the expansion of enzyme manufacturing and research in regions heavily reliant on imports, such as North America and Europe. Segments like industrial enzymes and therapeutic enzymes are most affected due to high import dependency. However, tariffs are also driving local manufacturing initiatives and encouraging investment in domestic enzyme production facilities, potentially reducing future supply chain risks.

The enzymes market research report is one of a series of new reports that provides enzymes market statistics, including enzymes industry global market size, regional shares, competitors with a enzymes market share, detailed enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the enzymes industry. This enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enzymes are proteins that typically act as biological catalysts, accelerating specific chemical reactions within cells. They function as catalysts in living organisms, regulating the speed of chemical processes without undergoing any permanent changes themselves.

The main types of enzymes include asparaginase, lipase, protease, nattokinase, chitinase, serratiopeptidase, collagenase, ligase, and others. Proteases are enzymes that catalyze proteolysis, breaking down proteins into smaller polypeptides or single amino acids and supporting the formation of new protein products. Enzymes are used in the treatment of leukemia, stomach disorders, tumors, skin ulcers, Gaucher disease, Fabry disease, and other conditions, and are employed by drug manufacturers, hospitals, private clinics, and research laboratories.

The enzyme market consists of sales of oxidoreductases, transferases, and hydrolases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.